All Clarivate websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.
Researchers from Etern Biopharma (Shanghai) Co. Ltd. recently reported the discovery and preclinical characterization of ETS-003, a novel YAP/TAZ-TEAD protein-protein interaction (PPI) inhibitor, being developed for the treatment of cancer.
It is known that the Hippo/YAP signaling pathway plays a crucial role in cell proliferation and tumorigenesis; is thought to contribute to 10% of all cancer types. TYK Medicines Inc. has presented a novel YAP/TEAD interaction inhibitor compound, TY-1054, as a potential approach for treating cancer with dysregulated Hippo/YAP pathway.
Cancer immunotherapy candidate BSI-508, a bispecific fusion molecule targeting PD-1 and CD47, is undergoing early development at Biosion Inc., who recently presented preclinical data on the product.
Inflammatory bowel disease (IBD) is a chronic, immunologically mediated disorder of the gastrointestinal tract in which tissue damage and sustained inflammation lead to long-term dysfunction of the gastrointestinal tract.
Interleukin-12 (IL-12) is a pleiotropic cytokine designated as a cytotoxic lymphocyte maturation factor and NK cell stimulator that interconnects innate and adaptive immunity. Studies in animal models have shown antitumor effects, but its translation into the clinic has been often linked to unacceptable toxicity.
It was previously shown that AXL overexpression is associated with poor prognosis, metastasis, as well as drug resistance in various hematological and solid tumors, and that inhibition of AXL phosphorylation could overcome drug resistance to FLT3 inhibitors. CTS-2016 is an AXL/FLT3 inhibitor being developed by Cytosinlab Therapeutics Co. Ltd. as a novel tyrosine kinase inhibitor for cancer.
Researchers from TYK Medicines Inc. presented the discovery and preclinical evaluation of a new cyclin-dependent kinase 274/6 (CDK2/4/6) inhibitor, TY-0540, being developed as an anticancer agent.
Researchers from Senelix Co. Ltd. described the preclinical characterization of the novel adiponectin receptor protein 1/2 (ADIPOR1/2) agonist SL-100, which is being developed for the treatment of dry eye disease (DED).
RSS
